Efficacy of third-line therapy using bevacizumab in a patient with metastatic colorectal cancer.
Bevacizumab is currently approved in association with first- and second-line 5-fluorouracil-based chemotherapy regimens for patients with metastatic colorectal cancer. Few data about the usefulness of bevacizumab in third-line settings are available. We describe a patient refractory to FOLFIRI and FOLFOX chemotherapy regimens who showed a dramatic and durable response to bevacizumab and FOLFIRI. We also review and discuss the available literature.
Departments of Hematology and Oncology, Centre Hospitalier Universitaire de Sherbrooke, Sherbrooke, QC.
J
J
Gaulin
R
R
Kotb
E
E
Turcotte
G
G
Berard
B
B
Sawan
G
G
Schmutz
P
P
Beauregard